文献库搜索 | GeneLibs

Xu(H),Yang(C),Fu(Q),Zeng(S),Yang(Y),Cao(Z)... Cell Oncol (Dordr) 2026-07-07

...PIK3CA promoter, thereby upregulating PIK3CA expression and hyperactivating the PI3K/AKT signaling pathway. Clinically, ...

Eghbalnia(A),Dadkhah(R),Riazi-Esfahani(H),... J Med Case Rep 2026-07-07

...PIK3CA gene, leading to dysregulated vascular development. While primarily affecting the skin and musculoskeletal system...

Wan(Y),Xu(P),Zhang(Y),Xu(J),Wang(B),Zhao(K... Front Surg None

...PIK3CA mutation, which led to a diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS). To our knowledge, this is the fi...

Liu(N),Ren(C),Ren(Y),Deng(S),He(Y),Lv(X),Z... Front Mol Biosci None

...PIK3CA, CDK12, MYC, and CCND1. The focal amplification subgroup exhibited significantly higher gene copy number (GCN) (3...

Li(J),Li(Y),Tan(Y),Zhou(C),Yao(X),Wang(J),... J Pathol 2026-07-08

...PIK3CA, MTOR, DNA repair genes, and epigenetic regulators. Pathogenic TP53 mutations were confined to lesions with marke...

Thibault(C),Blons(H),Allory(Y),Harba(A),Ro... Eur Urol Oncol 2026-07-08

...PIK3CA mutations, loss of chromosome 9, and widespread chromatin-remodeling gene alterations. MIBC displays high genomic...

Zhang(M),Niu(L),Lyu(H),Liu(Z),Zeng(H),Lu(Z... Chin Med J (Engl) 2026-07-07

...PIK3CA and BRCA1/2. Based on dose-limiting toxicities and preliminary efficacy, daily famitinib 10 mg combined with dalp...

Navaei(M),Karami(F),Jahanimoghadam(A),Zare... Cancer Invest 2026-07-09

...PIK3CA, BRAF, EGFR, ERBB2, FGFR3, MTOR, and TP53, along with KRAS, MET, and FGFR2, emerged as potential biomarkers. Addi...

Alvarez-Palacios(O),Ojeda-Campos(L),Rodríg... Rare Tumors None

...PIK3CA). The disease progressed rapidly despite CHOP chemotherapy, and the patient died shortly after diagnosis. This re...

Chou(LP),Lee(MY),Fang(CL),Tung(CL),Lin(IL)... Front Med (Lausanne) None

...PIK3CA, and PTEN mutations. Initially, he received trastuzumab and pembrolizumab. However, there was no clinical respons...